Efficacy and safety of nilotinib 800 mg daily in early chronic phase Ph+ chronic myeloid leukemia: Results of a phase II trial at 2 years. Background: BCR-ABL transcript levels have been reported to ...
Gene Expression Profiles of Tumor Biology Provide a Novel Approach to Prognosis and May Guide the Selection of Therapeutic Targets in Multiple Myeloma Although all authors completed the disclosure ...
E. Weisberg et al., "Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl," Cancer Cell, 7:129-41, February 2005. (Cited in 89 papers) Imatinib (Gleevec) stunned the world ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback